{"id":745272,"date":"2015-01-22T15:29:00","date_gmt":"2015-01-22T15:29:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/"},"modified":"2025-11-07T01:25:23","modified_gmt":"2025-11-07T06:25:23","slug":"merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/","title":{"rendered":"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, on<br \/>\n      behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc.,<br \/>\n      today announced that, in connection with the completion of the<br \/>\n      acquisition of Cubist by Merck, Cubist has commenced a tender offer (the<br \/>\n      \u201c<span class=\"bwuline\">Convertible Notes Tender Offer<\/span>\u201d) to<br \/>\n      repurchase, at the option of each holder, any and all of its outstanding<br \/>\n      2.50% Convertible Senior Notes due 2017 (the \u201c<span class=\"bwuline\">2017<br \/>\n      Convertible Notes<\/span>\u201d), 1.125% Convertible Senior Notes due 2018<br \/>\n      (the \u201c<span class=\"bwuline\">2018 Convertible Notes<\/span>\u201d) and 1.875%<br \/>\n      Convertible Senior Notes due 2020 (the \u201c<span class=\"bwuline\">2020<br \/>\n      Convertible Notes<\/span>\u201d and together with the 2017 Convertible Notes<br \/>\n      and 2018 Convertible Notes, the \u201c<span class=\"bwuline\">Convertible Notes<\/span>\u201d).<br \/>\n      Earlier in the day on January 21, 2015, Merck completed the tender offer<br \/>\n      for all of the outstanding shares of common stock of Cubist, consummated<br \/>\n      the merger of Cubist into Mavec Corporation, Inc., a wholly owned<br \/>\n      subsidiary of Merck, and terminated trading of Cubist\u2019s common stock on<br \/>\n      the Nasdaq Global Select Market, each of which constituted a Fundamental<br \/>\n      Change (as defined in each of the indentures governing the Convertible<br \/>\n      Notes (the \u201c<span class=\"bwuline\">Indentures<\/span>\u201d)) triggering<br \/>\n      Cubist\u2019s obligation to commence the Convertible Notes Tender Offer.\n    <\/p>\n<p>\n      Pursuant to the terms of the Convertible Notes Tender Offer, each holder<br \/>\n      of the Convertible Notes has the right (the \u201c<span class=\"bwuline\">Fundamental<br \/>\n      Change Repurchase Right<\/span>\u201d) to require Cubist to repurchase for<br \/>\n      cash its Convertible Notes, or any portion of the principal amount<br \/>\n      thereof that is equal to $1,000 or an integral multiple of $1,000, on<br \/>\n      February 23, 2015 (the \u201c<span class=\"bwuline\">Fundamental Change<br \/>\n      Repurchase Date<\/span>\u201d). The repurchase price (the \u201c<span class=\"bwuline\">Fundamental<br \/>\n      Change Repurchase Price<\/span>\u201d) for Convertible Notes validly<br \/>\n      surrendered and not validly withdrawn will be 100% of the principal<br \/>\n      amount of the Convertible Notes being repurchased, plus accrued and<br \/>\n      unpaid interest, if any, to, but excluding, the Fundamental Change<br \/>\n      Repurchase Date. Holders may surrender their Convertible Notes from<br \/>\n      January 22, 2015 until 11:59 p.m., Eastern Time, on February 19, 2015<br \/>\n      (the \u201c<span class=\"bwuline\">Fundamental Change Expiration Date<\/span>\u201d).<br \/>\n      Tenders of the Convertible Notes must be made prior to the expiration of<br \/>\n      the Convertible Notes Tender Offer and may be withdrawn at any time<br \/>\n      prior to the expiration of the Convertible Notes Tender Offer through<br \/>\n      compliance with the proper withdrawal procedures outlined in the<br \/>\n      Fundamental Change Repurchase Right Notice, Notice of Right to Convert,<br \/>\n      Notice of Entry into Supplemental Indenture and Offer to Repurchase to<br \/>\n      Holders of the Convertible Notes dated January 22, 2015 (the \u201c<span class=\"bwuline\">Offer<br \/>\n      to Repurchase<\/span>\u201d).\n    <\/p>\n<p>\n      To exercise the Fundamental Change Repurchase Right to have Cubist<br \/>\n      repurchase the Convertible Notes and receive payment of the Fundamental<br \/>\n      Change Repurchase Price, holders must validly surrender their<br \/>\n      Convertible Notes to The Bank of New York Mellon Trust Company, N.A. as<br \/>\n      paying agent (the \u201c<span class=\"bwuline\">Paying Agent<\/span>\u201d) prior to<br \/>\n      11:59 p.m., Eastern Time, on the Fundamental Change Expiration Date. The<br \/>\n      Bank of New York Mellon Trust Company, N.A., the trustee under the<br \/>\n      Indenture (the \u201c<span class=\"bwuline\">Trustee<\/span>\u201d), has informed<br \/>\n      Cubist that, as of January 22, 2015, all Convertible Notes are held<br \/>\n      through The Depository Trust Company (\u201c<span class=\"bwuline\">DTC<\/span>\u201d)<br \/>\n      and that there are no certificated Convertible Notes in non-global form.<br \/>\n      Accordingly, all Convertible Notes surrendered for repurchase or<br \/>\n      conversion must be delivered through the Automated Tender Offer Program<br \/>\n      transmittal procedures of DTC.\n    <\/p>\n<p>\n      In addition, Merck has also announced on behalf of Cubist that, pursuant<br \/>\n      to each Indenture, the Convertible Notes are convertible, at the option<br \/>\n      of the holder, at any time until February 23, 2015. The applicable<br \/>\n      Conversion Rate (as defined in the applicable Indenture) for 2017<br \/>\n      Convertible Notes is 34.66199631, for the 2018 Convertible Notes is<br \/>\n      13.17448859 and for the 2020 Convertible Notes is 13.51652926, in each<br \/>\n      case for such Convertible Notes converted prior to February 23, 2015.<br \/>\n      The right of holders to convert their Convertible Notes is separate from<br \/>\n      the Fundamental Change Repurchase Right. Convertible Notes that a holder<br \/>\n      has surrendered for repurchase pursuant to the Fundamental Change<br \/>\n      Repurchase Right may be converted only if such holder first validly<br \/>\n      withdraws such Convertible Notes from the Convertible Notes Tender Offer<br \/>\n      through compliance with the proper withdrawal procedures outlined in the<br \/>\n      Offer to Repurchase.\n    <\/p>\n<p>\n      Holders should review the Offer to Repurchase carefully and consult with<br \/>\n      their own financial and tax advisors. None of Cubist, Merck or any of<br \/>\n      their respective affiliates, their respective boards of directors,<br \/>\n      employees, advisors or representatives, the Trustee, the Paying Agent or<br \/>\n      the Conversion Agent are making any representation or recommendation to<br \/>\n      any holder as to whether or not to tender or refrain from tendering its<br \/>\n      Convertible Notes in the Convertible Notes Tender Offer, or to exercise<br \/>\n      their conversion rights (if at all).\n    <\/p>\n<p>\n      The Paying Agent and Conversion Agent for the Convertible Notes Tender<br \/>\n      Offer is The Bank of New York Mellon Trust Company, N.A., 525 William<br \/>\n      Penn Place, 38<sup>th<\/sup> Floor, Pittsburgh, Pa. 15259, Attention:<br \/>\n      Corporate Trust Administration, 412-236-1201. The Information Agent for<br \/>\n      the Convertible Notes Tender Offer is MacKenzie Partners, 105 Madison<br \/>\n      Avenue, New York, N.Y. 10016, 800-322-2885 or 212-929-5500. Any<br \/>\n      questions and requests for assistance in connection with the Convertible<br \/>\n      Notes Tender Offer or conversion of the Convertible Notes may be<br \/>\n      directed to the Paying Agent, the Conversion Agent and the Information<br \/>\n      Agent. The Offer to Repurchase detailing the purchase option and the<br \/>\n      conversion rights is being sent by Cubist to DTC as sole record owner of<br \/>\n      the Convertible Notes.\n    <\/p>\n<p>\n      This press release is for informational purposes only and does not<br \/>\n      constitute an offer to buy or the solicitation of an offer to sell the<br \/>\n      Convertible Notes. The Convertible Notes Tender Offer is being made only<br \/>\n      pursuant to a Tender Offer statement (including the offer to repurchase<br \/>\n      and related materials) that Cubist will file with the securities and<br \/>\n      exchange commission (\u201c<span class=\"bwuline\">SEC<\/span>\u201d) and thereafter<br \/>\n      distribute to its Noteholders. Noteholders and investors should read<br \/>\n      carefully the Tender Offer statement because it contains important<br \/>\n      information, including the various terms of, and conditions to, the<br \/>\n      Convertible Notes Tender Offer. Noteholders can obtain their documents<br \/>\n      when they are filed and become available free of charge from the SEC\u2019s<br \/>\n      website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=1701140db10d782748451abb9d7f31ab\" rel=\"nofollow\">www.sec.gov<\/a>,<br \/>\n      or by contacting Merck at 2000 Galloping Hill Road, Kenilworth, N.J.,<br \/>\n      07033, 908-740-4000.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=1d9e0cfbecc6d2b5818f5d69961460a3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=f374e5655bee0dc4a03e82e3f87cbece\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e610770456db6e562048617593fbe20a\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=d5cbba6203b20387119797c1ee549f90\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. Forward-looking statements include<br \/>\n      statements regarding the timing and closing of the Convertible Notes<br \/>\n      Tender Offer and any assumptions underlying the foregoing. These<br \/>\n      statements are based upon the current beliefs and expectations of<br \/>\n      Merck\u2019s management and are subject to significant risks and<br \/>\n      uncertainties. There can be no guarantees with respect to pipeline<br \/>\n      products that the products will receive the necessary regulatory<br \/>\n      approvals or that they will prove to be commercially successful. If<br \/>\n      underlying assumptions prove inaccurate or risks or uncertainties<br \/>\n      materialize, actual results may differ materially from those set forth<br \/>\n      in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions; and timing of the<br \/>\n      Convertible Notes Tender Offer.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise except as required by applicable law. Additional factors that<br \/>\n      could cause results to differ materially from those described in the<br \/>\n      forward-looking statements can be found in Merck\u2019s 2013 Annual Report on<br \/>\n      Form 10-K and the company\u2019s other filings with the Securities and<br \/>\n      Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51025064&amp;newsitemid=20150122006325&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=714240a97c3eebfd46deae496bddd68e\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>Steve Cragle,        908-740-1801<br \/>or<br \/>Investor:<br \/>Joe Romanelli, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the \u201c Convertible Notes Tender Offer \u201d) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d). Earlier in the day on January 21, 2015, Merck completed the tender offer for all of the outstanding shares of common stock of Cubist, consummated the merger of Cubist into Mavec Corporation, Inc., a wholly owned subsidiary of Merck, and terminated trading of Cubist\u2019s common stock on<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745272","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the \u201c Convertible Notes Tender Offer \u201d) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d). Earlier in the day on January 21, 2015, Merck completed the tender offer for all of the outstanding shares of common stock of Cubist, consummated the merger of Cubist into Mavec Corporation, Inc., a wholly owned subsidiary of Merck, and terminated trading of Cubist\u2019s common stock on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:23+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/\",\"name\":\"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-01-22T15:29:00+00:00\",\"dateModified\":\"2025-11-07T06:25:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/","og_locale":"en_US","og_type":"article","og_title":"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the \u201c Convertible Notes Tender Offer \u201d) to repurchase, at the option of each holder, any and all of its outstanding 2.50% Convertible Senior Notes due 2017 (the \u201c 2017 Convertible Notes \u201d), 1.125% Convertible Senior Notes due 2018 (the \u201c 2018 Convertible Notes \u201d) and 1.875% Convertible Senior Notes due 2020 (the \u201c 2020 Convertible Notes \u201d and together with the 2017 Convertible Notes and 2018 Convertible Notes, the \u201c Convertible Notes \u201d). Earlier in the day on January 21, 2015, Merck completed the tender offer for all of the outstanding shares of common stock of Cubist, consummated the merger of Cubist into Mavec Corporation, Inc., a wholly owned subsidiary of Merck, and terminated trading of Cubist\u2019s common stock on","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:23+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/","name":"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-01-22T15:29:00+00:00","dateModified":"2025-11-07T06:25:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150122006325r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-on-behalf-of-its-wholly-owned-subsidiary-cubist-pharmaceuticals-announces-tender-offer-for-cubists-2-50-convertible-senior-notes-due-2017-1-125-convertible-senior-notes-due-2018-and\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist\u2019s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e0b14687-9d58-42d6-9aa5-d4881d8469c7","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745272\/revisions"}],"predecessor-version":[{"id":3674691,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745272\/revisions\/3674691"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745272"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}